Protocols

Based on available clinical trial evidence, nicotinamide riboside (Niagen) has been studied using various dosing protocols, though specific dosing details from individual studies are not provided in the current evidence base.

The clinical trials identified include investigations in:

Systolic heart failure (completed Phase 1/2 trial)
Metabolic health (completed study)
Exercise supplementation (completed study)
Mitochondrial biogenesis (completed study)
Injectable administration and tolerability (currently recruiting)

However, the evidence provided does not contain specific dosing protocols, administration schedules, or duration of treatment from these completed trials. The research appears to focus on various therapeutic applications including cardiovascular health, metabolic function, and exercise performance.

One ongoing study is examining injectable administration of Niagen+ compared to NAD+, suggesting research into alternative delivery methods beyond oral supplementation.

Important Limitations: The current evidence does not provide sufficient detail about specific dosing protocols, administration schedules, treatment duration, or safety monitoring parameters used in clinical studies. More detailed protocol information would be needed to establish evidence-based dosing recommendations.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Dosing and administration of nicotinamide riboside should only be determined by qualified healthcare providers based on individual patient assessment and current clinical guidelines.

Niagen (Nicotinamide Riboside)

Member access required